Study guide
9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
Key Takeaways Explain This Topic AI
Menopause can be diagnosed clinically in women over 45 with typical symptoms; FSH testing is reserved for women aged 40–45 with symptoms or under 40 with suspected premature ovarian insufficiency.
Women with a uterus who take oestrogen HRT also need a progestogen to prevent endometrial hyperplasia and cancer.
Transdermal oestrogen does not increase venous thromboembolism risk above baseline, so it is preferred for women with VTE risk factors or a BMI over 30.
Couples are investigated for subfertility after 1 year of regular unprotected intercourse, or sooner if the woman is 36 or over or a cause is known (NICE CG156).
Stress urinary incontinence is treated first with supervised pelvic floor muscle training for at least 3 months, and urge incontinence with bladder training for at least 6 weeks (NICE NG123).
Last updated: October 2026
- Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
- Menopause (NICE NG23)
The menopause is the final menstrual period, confirmed after 12 months of amenorrhoea ; the average age in the UK is 51.
Diagnosis: clinical in women over 45 with vasomotor symptoms or irregular periods; FSH is not needed . Consider FSH in women aged 40–45 with symptoms, and in women under 40 with suspected premature ovarian insufficiency. FSH is unreliable in women taking combined hormonal contraception or high-dose progestogens.
Symptoms: hot flushes and night sweats, mood change, poor sleep, joint aches, reduced libido and genitourinary syndrome of menopause (vaginal dryness, dyspareunia, urgency, recurrent UTI). Long-term, oestrogen deficiency increases osteoporosis and cardiovascular risk.
Premature ovarian insufficiency (POI): menopause before 40, with raised FSH on two samples 4–6 weeks apart . Offer hormone therapy (HRT or combined hormonal contraception) at least until the average age of menopause to protect bones and the heart.
Hormone Replacement Therapy (HRT)
- Situation Regimen
- No uterus (hysterectomy) Oestrogen alone
Uterus, perimenopausal (period within the last 12 months) Sequential (cyclical) combined HRT : monthly withdrawal bleed
- Uterus, postmenopausal (12 months without periods) Continuous combined HRT
- Uterus, also needs contraception Oestrogen with a 52 mg levonorgestrel IUS for endometrial protection
- Vaginal symptoms only Vaginal oestrogen (can be used long-term and with systemic HRT)
Important
Endometrial Protection: Unopposed oestrogen in a woman with a uterus causes endometrial hyperplasia and cancer, so a progestogen must be added. Persistent unscheduled bleeding on HRT (beyond the first 3–6 months, or after a period of no bleeding) needs investigation.
Benefits and risks (NICE NG23): HRT is the most effective treatment for vasomotor symptoms and prevents osteoporosis.
VTE: oral oestrogen increases the risk; transdermal oestrogen does not increase it above baseline , so it is preferred with VTE risk factors or BMI over 30.
Breast cancer: combined HRT causes a small increase that depends on duration and falls after stopping; oestrogen-alone HRT causes little or no change.
Stroke: small increase with oral (not transdermal) oestrogen.
Contraindications include current or past breast cancer, undiagnosed vaginal bleeding, active VTE or arterial disease, and untreated endometrial hyperplasia.
Alternatives: CBT for vasomotor and mood symptoms; non-hormonal drugs such as some SSRIs or SNRIs, clonidine or gabapentin (avoid fluoxetine and paroxetine with tamoxifen).
Contraception is still needed for 2 years after the last period if it occurred under 50, and 1 year if over 50 (HRT is not contraceptive).
Subfertility (NICE CG156)
Definition: failure to conceive after 1 year of regular unprotected intercourse . Investigate earlier if the woman is 36 or over , or there is a known cause (amenorrhoea, previous pelvic surgery or PID, undescended testes, chemotherapy).
Causes: male factor (about 30%), ovulatory disorders (mainly PCOS ), tubal damage ( chlamydia , PID, endometriosis, surgery), uterine factors, and unexplained subfertility.
Initial investigations:
Semen analysis (repeat after about 3 months if abnormal).
Mid-luteal progesterone (day 21 of a 28-day cycle, or 7 days before the expected period) to confirm ovulation.
Chlamydia screening before uterine instrumentation.
Tubal patency: hysterosalpingography (or hysterosalpingo-contrast-ultrasonography) if there are no comorbidities; laparoscopy and dye test if PID, endometriosis or previous surgery is suspected.
Management: lifestyle advice ( BMI 19–30 , stop smoking, limit alcohol, folic acid); ovulation induction (letrozole or clomifene, under specialist monitoring for multiple pregnancy) for anovulatory PCOS; tubal surgery; IVF (NICE: up to 3 full cycles for women under 40 who have not conceived after 2 years of regular intercourse or 12 cycles of artificial insemination; 1 cycle for women aged 40–42 meeting criteria); intracytoplasmic sperm injection for severe male factor. Ovarian hyperstimulation syndrome (abdominal distension, ascites, haemoconcentration, VTE risk) is a serious complication of stimulation.
Pelvic Organ Prolapse
Descent of the bladder ( cystocele ), rectum ( rectocele ), uterus or vaginal vault, due to weakened pelvic floor support. Risk factors: vaginal childbirth , age, menopause, obesity, chronic cough and constipation. Symptoms: dragging sensation, a lump, urinary or bowel emptying difficulty.
Conservative: pelvic floor muscle training (at least 16 weeks) , weight loss, treating constipation and cough, vaginal oestrogen.
Vaginal pessaries (ring or shelf) for women who want to avoid surgery.
Surgery (anterior or posterior repair, vaginal hysterectomy, sacrocolpopexy). The use of transvaginal mesh for prolapse has been restricted in the UK since 2018.
Urinary Incontinence in Women (NICE NG123)
Assessment: urine dipstick for infection, 3-day bladder diary , post-void residual if voiding problems are suspected, and pelvic examination.
Type Features First-Line Management Further Options
Stress Leakage on coughing, sneezing or exercise; after childbirth Supervised pelvic floor muscle training for at least 3 months ; weight loss Surgery (colposuspension, autologous fascial sling; mid-urethral tapes under restrictions); duloxetine only if surgery is declined
Urge (overactive bladder) Urgency, frequency, nocturia, leakage on the way to the toilet Bladder training for at least 6 weeks ; reduce caffeine; review fluid intake Antimuscarinic (avoid oxybutynin in frail older women because of cognitive effects) or mirabegron ; botulinum toxin injection; sacral nerve stimulation
Mixed Both Treat the predominant symptom first As above
Overflow Dribbling with incomplete emptying Look for obstruction or neurological cause; catheterisation Specialist referral
Red flags needing urgent referral include visible haematuria, recurrent UTIs with haematuria in women 40 or over, suspected pelvic mass, and a palpable bladder after voiding.
Loading diagram...